Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9
Open Access
- 18 September 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (18) , 10095
Abstract
Ocular hypertension (OHT) is a serious adverse effect of the widely prescribed glucocorticoid (GC) therapy and, if left undiagnosed, it can lead to glaucoma and complete blindness. Previously, we have shown that the small chemical chaperone, sodium-4-phenylbutyrate (PBA), rescues GC-induced OHT by reducing ocular endoplasmic reticulum (ER) stress. However, the exact mechanism of how PBA rescues GC-induced OHT is not completely understood. The trabecular meshwork (TM) is a filter-like specialized contractile tissue consisting of TM cells embedded within extracellular matrix (ECM) that controls intraocular pressure (IOP) by constantly regulating aqueous humor (AH) outflow. Induction of abnormal ECM deposition in TM is a hallmark of GC-induced OHT. Here, we investigated whether PBA reduces GC-induced OHT by degrading abnormal ECM deposition in TM using mouse model of GC-induced OHT, ex vivo cultured human TM tissues and primary human TM cells. We show that topical ocular eye drops of PBA (1%) significantly lowers elevated IOP in mouse model of GC-induced OHT. Importantly, PBA prevents synthesis and deposition of GC-induced ECM in TM. We report for the first time that PBA can degrade existing abnormal ECM in normal human TM cells/tissues by inducing matrix metalloproteinase (MMP)9 expression and activity. Furthermore, inhibition of MMPs activity by chemical-inhibitor (minocycline) abrogated PBA’s effect on ECM reduction and its associated ER stress. Our study indicates a non-chaperone activity of PBA via activation of MMP9 that degrades abnormal ECM accumulation in TM.Keywords
Funding Information
- National Institutes of Health (R01 EY028616; EY026177)
This publication has 57 references indexed in Scilit:
- Overexpression of SPARC in Human Trabecular Meshwork Increases Intraocular Pressure and Alters Extracellular MatrixInvestigative Ophthalmology & Visual Science, 2013
- Topical Ocular Sodium 4-Phenylbutyrate Rescues Glaucoma in a Myocilin Mouse Model of Primary Open-Angle GlaucomaInvestigative Ophthalmology & Visual Science, 2012
- In Vivo Ocular Efficacy Profile of Mapracorat, a Novel Selective Glucocorticoid Receptor Agonist, in Rabbit Models of Ocular DiseaseInvestigative Ophthalmology & Visual Science, 2011
- Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia controlMolecular Genetics and Metabolism, 2010
- Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse ModelNeuropsychopharmacology, 2009
- Corticosteroid-induced glaucoma: a review of the literatureEye, 2005
- Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-PhenylbutyrateMolecular Therapy, 2002
- Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasoneEye, 2000
- Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshworkCurrent Eye Research, 1995
- Corticosteroid Treatment and Trabecular Meshwork Proteases in Cell and Organ Culture SupernatantsExperimental Eye Research, 1993